Because LGL leukemia has a chronic, indolent course, patient cells may not be dividing all that rapidly; thus, the effect of blocking cell proliferation may be hard to discern and a less important ...

Hu-Mikβ1 was evaluated in a Phase I clinical trial in patients with T-cell large granular lymphocyte leukemia. Hu-Mikβ1 was shown to be safe in Phase I trials; however, no therapeutic efficacy ...